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Abstract
Background: Hirschsprung disease (HSCR) is a congenital malformation of the hindgut produced
by a disruption in neural crest cell migration during embryonic development. HSCR has a complex
genetic etiology and mutations in several genes, mainly the RET proto-oncogene, have been related
to the disease. There is a clear predominance of missense/nonsense mutations in these genes
whereas copy number variations (CNVs) have been seldom described, probably due to the
limitations of conventional techniques usually employed for mutational analysis.
Methods: In this study we have aimed to analyze the presence of CNVs in some HSCR genes
(RET, EDN3, GDNF and ZFHX1B) using the Multiple Ligation-dependent Probe Amplification
(MLPA) approach.
Results: Two alterations in the MLPA profiles of RET and EDN3 were detected, but a detailed
inspection showed that the decrease in the corresponding dosages were due to point mutations
affecting the hybridization probes regions.
Conclusion: Our results indicate that CNVs of the gene coding regions analyzed here are not a
common molecular cause of Hirschsprung disease. However, further studies are required to
determine the presence of CNVs affecting non-coding regulatory regions, as well as other
candidate genes.
Background
Hirschsprung disease (HSCR, OMIM 142623) is a con-
genital malformation of the hindgut produced by a dis-
ruption in neural crest cell migration during embryonic
development. This disorder results in an absence of intra-
mural ganglion cells in the submucosal and myenteric
plexuses, producing a functional intestinal obstruction
[1,2]. HSCR has an estimated incidence of 1/5000 in live
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births, with a non-mendelian inheritance, reduced pene-
trance and male predominance. Although familial forms
exist, the vast majority of cases are sporadic. In addition,
HSCR can present as an isolated trait (70% of the cases),
or in association with chromosomal abnormalities, neu-
rodevelopmental disorders and a variety of additional iso-
lated anomalies and syndromes [2].
HSCR has a multifactorial genetic etiology with several
genes described as being associated with isolated or syn-
dromic forms of the disease. These genes are usually
involved in the neural crest cell development and migra-
tion that gives rise to the enteric nervous system (ENS).
Undoubtedly, the RET proto-oncogene is considered the
major disease-causing locus in HSCR and has been exten-
sively studied in different series of HSCR patients. Tradi-
tional mutations within RET coding sequence have been
detected in up to 50% of familial cases and in 10-20% of
sporadic forms of the disease [1,2]. Moreover, a common
non-coding RET variant within a conserved enhancer-like
sequence in intron 1 has been reported to be significantly
associated with HSCR susceptibility and to make a 20-fold
greater contribution to risk than conventional coding
mutations do [3]. HSCR can, therefore, be defined as a
complex disorder with non-mendelian inheritance that
requires RET and other interacting disease susceptibility
alleles. As is the case with many other complex diseases,
the manifestation of the phenotype may result from the
combination of pathogenic events in one or several genes,
acting in an additive or multiplicative manner. These
additional events are therefore necessary not only to
explain the disease incidence but also its complex pattern
of inheritance.
Mutations in other genes encoding proteins involved in
the RET pathway, such as GDNF, NTN, or GFRA1, have
been also reported in HSCR patients. However, they affect
a minority of cases and frequently appear in combination
with additional contributory factors, like RET mutations
or trisomy 21 [1,2].
The second major HSCR gene is the one encoding the
Endothelin receptor B (EDNRB), which presents a muta-
tional rate of approximately 5% in HSCR patients. Also
participating in the same EDNRB pathway, EDN3  and
ECE1 have seldom been reported to present mutations
related to syndromic forms of HSCR [1,2].
A third pathway involved in the ENS formation, NTF3-
NTRK3, showed evidence of being related to HSCR, as
mutations in both NTF3 and NTRK3 genes were identified
in isolated patients [4,5]. Nevertheless, additional studies
are required to determine their real involvement in the
disease.
Finally, other genes encoding for transcription factors
(SOX10, ZFHX1B, PHOX2B, TCF4), or other cell elements
(KIAA1279), have been eventually related to different syn-
dromes that include Hirschsprung [1,2].
Regarding the nature of the mutational events leading to
HSCR phenotype, there is a clear predominance of mis-
sense/nonsense mutations, especially in RET and EDNRB
http://www.hgmd.cf.ac.uk/ac/index.php. Small deletions
or insertions and splicing mutations in RET have been
found in a few patients (see HGMD), whilst they are rarely
reported in other genes. In contrast, no duplications and
only a gross deletion affecting the entire sequence of RET
have been reported to date [6]. A possible explanation for
this low rate of copy number variations (CNV) related to
HSCR is that the techniques usually employed for muta-
tional screening, such as SSCP, dHPLC or sequencing
analysis, are not adequate to identify these types of rear-
rangements.
In light of this information, in the present study we have
sought to study the presence of CNVs in RET, the "major
HSCR gene" in our series of patients, using the Multiple
Ligation-dependent Probe Amplification (MLPA) tech-
nique, which is one of the best methods for detecting
alterations in genes dosages [7]. In addition, another 3
genes responsible for a minority of the cases, (GDNF,
EDN3, ZFHX1B) were simultaneously analyzed as the
MLPA kit used also contained probes for their detection.
Methods
Patients and Control Subjects
A total of 208 isolated HSCR patients from Spain (22%
female, 77% male) were involved in this study. 188 of
these patients were sporadic cases, whilst 20 were familial
forms belonging to 13 different families. RET  coding
mutations had been found in 23 of the 188 sporadic cases
(mutational rate: 12%), and in 4 of the 13 familial forms
(mutational rate: 31%) [reference [8] and unpublished
data]. In addition, 80% of the patients were heterozygous
or homozygous for the "RET enhancer mutation" [refer-
ence [9] and unpublished data]. Regarding the mutational
status for the remaining "HSCR genes", a multiplex family
with 2 affected members presenting mutations of RET,
NTRK3 and EDN3 genes [5,10], and a sporadic patient
carrying a NTF3  mutation [4] are worthy of mention.
Finally, EDNRB coding mutations were found in 5 spo-
radic patients and in 1 familial case (unpublished data).
No other mutational events related to HSCR were found
in the remaining HSCR genes analyzed by our group.
Given the complex nature of Hirschsprung disease, in
which the contribution of several loci seems to be neces-
sary for the manifestation of the phenotype, we included
our whole series of patients in the present study despite
their mutational status for RET and other genes.BMC Medical Genetics 2009, 10:119 http://www.biomedcentral.com/1471-2350/10/119
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In addition, we also included a group of 10 normal con-
trols comprising unselected, unrelated, race, age, and sex-
matched individuals. They were all healthy voluntary
donors, who came to the Hospital for other reasons and
did not present any symptoms suggestive of HSCR.
Informed consent was obtained from all the participants
for clinical and molecular genetic studies. The study was
approved by the Ethics Committee for clinical research in
the Hospital Universitario Virgen del Rocio of Seville, and
complies with the tenets of the declaration of Helsinki.
MLPA analysis
The MLPA-Hirschsprung test kit (P169) was supplied by
MRC Holland, Amsterdam, Netherlands. This kit contains
41 different probes designed to detect alterations in the
copy number of one or more exons in four genes involved
in either isolated or syndromic forms of HSCR (RET,
ZFHX1B, EDN3 and GDNF). In addition, the kit also con-
tains 5 control fragments which hybridize with different
regions of the genome. The MLPA reaction was performed
in a MJ Research Thermal Cycler with a heated lid following
MRC Holland DNA - detection quantification protocol
http://www.mrc-holland.com/WebForms/ WebForm
Main.aspx?Tag=wl2zCji\rCGANQgZPuTixtCplCA1mmwJ
oFo/xHPnTgc|.
Fragment analysis was performed using the 3730 DNA
analyzer (Applied Biosystems, Foster City, CA, USA) and
for data analysis we used GeneMarker v 1.6 (Softgenetics
L.L.C). We normalized the samples by using the peak
heights values, and included control individuals who had
previously been confirmed to have no CNV of the studied
genes. Furthermore, duplicate assays were performed to
check the accuracy of the analysis results.
Results
The main aim of this study was to determine if our HSCR
patients were carriers of variations of the number of cop-
ies of RET and other 3 genes related to the disease. It has
been previously described that polymorphisms or single
base mutations located within the probe binding regions
may affect MLPA results [7]. Therefore, we carried out an
screening of point mutations prior to the MLPA tests, by
denaturing high performance liquid chromatography
(dHPLC) and direct sequencing of the coding regions of
the 4 genes included in the kit. As a result, several point
sequence changes were identified, the majority of them
being common polymorphisms[8,10,11]. Subsequently,
we performed the MLPA technique on our series of 208
patients with the MLPA-Hirschsprung test kit (MRC Hol-
land) analyzing RET  (exons 1-21), GDNF  (exons1-4),
EDN3 (exons 1-5) and ZFHX1B (exons 1-10). Our analy-
sis revealed that two of these patients presented an appar-
ent alteration in the gene dosage of RET  and  EDN3
respectively, that consisted in a signal decrease of 50%
when compared with the control individuals. The profiles
obtained for both individuals are shown in Figure 1. The
rest of the patients presented normal dosages for all the
exons studied.
We therefore investigated the exact probe binding sites for
the 2 altered exons and sought to confirm if they were
affected by the presence of any sequence variant previ-
ously detected in the corresponding patients. The first
patient presented a decrease in exon 17 of RET, but the
neighboring exons' dosages were completely normal. The
previous  RET  mutational screening by dHPLC of this
patient had shown that he carried the point mutation
c.2859T>A (p.Pro953Lys) in heterozygosis, which as sus-
pected is located within the hybridization probe region
corresponding to exon 17 (unpublished data, Figure 2).
The second patient presented a decrease in the dosage of
exon 4 of EDN3 and an inspection of the previous results
from the EDN3 dHPLC screening showed that he carried
a 2 nucleotides deletion, c.572delAA (p.Lys191ArgfsX59),
affecting the corresponding hybridization probe region
([11], Figure 2). Both RET  c.2859T>A and EDN3
c.572delAA variants were found to be absent in 200 nor-
mal controls [8,10,11], and in silico analysis predicted a
damaging effect for both of them, which suggest that these
variants may be involved in the manifestation of the
HSCR phenotype in these patients, although probably in
combination with still unidentified genetic events at other
loci [8,10,11].
Discussion
HSCR has a complex genetic etiology and several genes
have been reported to be implicated in the disease. The
RET  proto-oncogene has been described as the major
HSCR gene, and over 100 mutations have been identified
including large chromosomal deletions which encompass
the whole RET sequence, microdeletions and insertions,
splicing, and nonsense and missense mutations [2], the
last mutations being the most frequent alterations found
in HSCR patients. Missense/nonsense variants are also the
most commonly described events in the remaining genes
related to HSCR, in contrast with gross deletions or CNVs
that have seldom been reported. Possible factors contrib-
uting to this fact could be that point mutations and small
deletions/insertions are easily detected by typical screen-
ing methods based on conventional PCR, and large chro-
mosomal rearrangements are identified by cytogenetic
techniques, whereas none of the 2 approaches are power-
ful enough and adequate to detect CNVs affecting specific
regions corresponding to a few kilobases [7]. Therefore we
decided to analyze our HSCR series using the MLPA tech-
nique, which allows medium-size alterations in theBMC Medical Genetics 2009, 10:119 http://www.biomedcentral.com/1471-2350/10/119
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number of copies to be detected, by simultaneously
screening RET, EDN3, GDNF and ZFHX1B.
2 patients with alterations in the MLPA profile of exon 17
of RET, and exon 4 of EDN3 respectively were identified.
However, a detailed inspection showed that such varia-
tions were not actual changes of the copy number but a
fail on the corresponding probes hybridization processes.
MLPA is a comparative method designed for the effective
detection of variations in gene dosage making estimating
the gene copy number possible. This method is being used
extensively in the molecular diagnosis of a wide range of
diseases caused by deletions or duplications of one or
more exons in specific genes. The main disadvantage of
using this technique is the short length of the hybridizing
region of the MLPA probes (20-30 nucleotides), which
means that nucleotide mismatches at the corresponding
probe binding sites may hinder the hybridization process
and lead to an apparent deletion being detected, as has
been observed here. Although other techniques such as
Comparative Genomic Hibridization arrays (CGH array)
are considered the best method for CNVs detection, MLPA
provides us with a way of identifying CNVs in a quick and
simple way, that is effective enough to achieve our specific
aims. Our results appear to indicate that CNVs are not a
common molecular cause of Hirschsprung disease. In fact,
of the 4 simultaneously analyzed genes, only RET  has
shown to have a major impact on the disease, while the
rest are only responsible for a minority of cases. A possi-
bility still remains that other HSCR genes that have not
been evaluated in the present study may present CNVs
responsible for a percentage of HSCR cases.
MLPA profiles for control individuals (red), and for the HSCR patients (blue) Figure 1
MLPA profiles for control individuals (red), and for the HSCR patients (blue). For these HSCR cases, an increase in 
the dosage of EDN3 exon 4 (a) and RET exon 17 (b) can be observed.
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Conclusion
Our results appear to indicate that CNVs in the coding
region of RET and the other 3 HSCR related genes here
tested are not a common molecular cause of Hirschsprung
disease, at least in the Spanish population. It would be
interesting to analyze other genes such as EDNRB, the sec-
ond major gene in HSCR, in future MLPA studies. In addi-
tion, the MLPA probes used here have been designed for
only scanning the coding sequence of these genes, mean-
ing that intronic and UTR regions are missed out. Given
the prominent role of the RET enhancer mutation within
intron 1 in the context of HSCR (3), revealing the great rel-
evance of the non-coding elements in the pathogenesis of
the disease, it would be also advisable to include such
regions in additional future MLPA analyses. Therefore,
further studies are warranted to completely rule out CNVs
as the molecular cause of some forms of Hirschsprung dis-
ease.
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